✦ LIBER ✦

Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy

✍ Scribed by Stinchcombe, Thomas E.; Morris, David E.; Moore, Dominic T.; Bechtel, John H.; Halle, Jan S.; Mears, Andrea; Deschesne, Katherine; Rosenman, Julian G.; Socinski, Mark A.

Book ID: 119319334
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 164 KB
Volume: 52
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2005.11.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-95 Combined modality therapy in a popu

O-95 Combined modality therapy in a population-based cohort of patients with stage III Non-small cell lung cancer

✍ Wai, Elaine S.; Moravan, Veronika; Truong, Pauline; Berthelet, Eric; Lim, Jan T. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

FDG Uptake Predicts Recurrence and Survi

FDG Uptake Predicts Recurrence and Survival in Patients with Unresectable Stage III Non-small Cell Lung Cancer Treated with 74 Gy (RBE) Proton Therapy and Chemotherapy

✍ Z. Xiang; H. Wen; E. Jeremy; M. O'Reilly; R. Komaki; J.D. Cox; J.Y. Chang 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Lung function changes and pulmonary comp

Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment

✍ Maas, K.W.; van der Lee, I.; Bolt, K.; Zanen, P.; Lammers, J.W.J.; Schramel, F.M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 211 KB

2142 Patterns of failure in locally adva

2142 Patterns of failure in locally advanced (stage III) non-small cell carcinoma of the lung treated with combined modality therapy

✍ Peter B. Hardin; Diance C. Recine; Salitha Reddy; L.Penfield Faber; William Warr 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Survival is better predicted with a new

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy

✍ Berghmans, T.; Lafitte, J.J.; Thiriaux, J.; VanHoutte, P.; Lecomte, J.; Efremidi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 126 KB

P-588 Tumor responsiveness to combined m

P-588 Tumor responsiveness to combined modality therapy (CMT) is highly significant predictor of survival for patients with locally advanced non-small cell lung cancer(LANSCLC)

✍ Kim, Dong Wook; Shyr, Yu; Akerley, Wallace L.; Choy, Hak 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 360 KB